Goldline Pharmaceutical IPO - Company Analysis
Goldline Pharmaceutical IPO is a bookbuild issue of promotor Goldline Pharmaceutical limited of Rs. 11.61 Cr. Goldline owns a brand of pharmaceutical products, which has five segments. These are:
Goldline Pharma: Contains 42 products dedicated for medical practitioners like physicians, orthopedicians, chest physicians, ENT physicians, surgeons of various specialties, physicians of gastroenterology, neurology, and urology.
Goldline Cardinal: A specialty division with 54 medical products.
Goldline Aayushman: A specialty division with 18 products for the medical practitioners of general medicine, pediatrics, child and neonatal medicine.
Goldline InLife: A specialty division with 22 products for physicians and super specialty surgeons, as well as Critical Care and Intensivists.
Goldline Wellness: Contains 10 products. Supportive care during the treatment of cancer.
Goldline Pharmaceutical IPO Details
The Goldline Pharmaceutical IPO will open on 12 May 2026 and close on 14 May 2026 with allotment on 15 May and initiation of refunds on 18 May 2026. The new SME IPO of Rs. 11.61 crores is a completely fresh issue of 0.27 Crores shares.
The expected date of The Goldline Pharmaceutical IPO listing is 19th May 2026 on the BSE and SME. The Goldline Pharmaceutical IPO Price Band is Rs. 41 to Rs. 43.
IPO Timetable (Tentative)
Click to open free demat account and apply for the IPO.
Company Financials
(Amount in Cr)
Cash Flows
(Amount in lac)
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The company plans to use the Net Proceeds from the Issue to accomplish the following objectives:
Part payment and/or full payment of several borrowings availed by the Company. ~ Rs. 8.35 Cr.
General Corporate Purposes.
Part payment and/or full payment of several borrowings availed by the Company. ~ Rs. 8.35 Cr.
General Corporate Purposes.
Listed Peers of Goldline Pharmaceutical Ltd.
Valuation
Evaluation of P/E Ratio
If we assume for the year ending FY 2025, the EPS is Rs. 4.10 for the previous year, that gives us a P/E Ratio of 10.48x.
IPO's Strengths
Promoters and Management Team with Industry Knowledge and Experience
Asset light Business Model and Competitive Products
Scalable Business Model
Wide and Diverse Product Range
IPO's Weaknesses
Dependence on third-party manufacturers.
Regulatory compliance and filing risk.
Market analysis and product selection risk
Goldline Pharmaceutical IPO GMP (Grey Market Premium)
The Goldline Pharmaceutical IPO GMP, as of writing this on May 15, 2026, is Rs. 15.
Goldline Pharmaceutical IPO Summary
IPO Lot Details
Goldline Pharmaceutical offers retail investors the option to purchase a minimum of 2 Lots (6,000 Shares) for a total cost of Rs. 2,58,000, and multiples thereof. For HNI investors, a close minimum of 3 Lots (9,000 Shares) have to be taken for a total cost of Rs. 3,87,000.
Goldline Pharmaceutical IPO Allotment Status
To check to Goldline Pharmaceutical IPO Allotment Status, please visit the official Registrar’s website as well as BSE’s website, the links of which are provided below.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Goldline Pharmaceutical Ltd.
Amol Laxmikant Mujumdar
Swapan Premprakash Khandelwal
IPO Lead Managers
Cumulative Capital Pvt. Ltd.
Dividend Policy
The company has not paid a dividend since its incorporation.
Conclusion
Goldline Pharmaceuticals plans its IPO on the BSE on May 12th. The IPO is an ₹11.61 crore issue priced at ₹41-₹43 per share. It will also close on May 14th. The company plans to use the funds from the IPO for general corporate purposes and to repay or prepay outstanding loans.
As of May 11, 2026, their FY2025 financials show the company completed the fiscal year with a total income of ₹28.06 crore, ₹2.83 crore PAT, 35.83% ROE, 38.45% ROCE, 10.48x P/E, and a GMP of ₹16.
To Read the Prospectus of the Company click here to Download the DRHP.
DISCLAIMER: This blog does not constitute any buy or sell recommendation. No investment or trading advice is being provided. The content is intended solely for educational and informational purposes. Investors should consult a qualified financial advisor before making any investment decisions.
